Brief: Novabay Pharmaceuticals Announces Agreement With Biostem Technologies To Commercialize Amniotic Tissue Allograft
11/09/2023 13:34
Sept 11 (Reuters) - Biostem Technologies Inc BSEM.PK :
* NOVABAY PHARMACEUTICALS ANNOUNCES AGREEMENT WITH BIOSTEM
TECHNOLOGIES TO COMMERCIALIZE AMNIOTIC TISSUE ALLOGRAFT AS
AVENOVA ALLOGRAFT
Source text for Eikon: ID:nBw5PkYYTa
Further company coverage: BSEM.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Stablecoin Development
See all newsBrief: Stablecoin Development Corporation Reports First Quarter 2026 Financial Results
Brief: Tether Says Participated In A $134 Million Financing Round For Stablecoin Development Corporation
Brief: Novabay Pharmaceuticals Announces Name Change To Stablecoin Development Corporation
Brief: Novabay Pharmaceuticals Says David Lazar Resigns As CEO
Brief: NovaBay Pharmaceuticals Files For Mixed Shelf Of Up To $200 Million - SEC Filing